S. Voleti

Identification of SGLT2 inhibitor Ertugliflozin as a treatment for COVID-19 using computational and experimental paradigm

This study identifies Ertugliflozin as a potential treatment for COVID-19 through computational screening and experimental validation of its ability to inhibit RBD-ACE2 binding and modulate inflammatory responses.

Tyrosine Kinase Inhibitor Family of Drugs as Prospective Targeted Therapy for COVID-19 Based on In Silico And 3D-Human Vascular Lung Model Studies

This study evaluates four tyrosine kinase inhibitors for their anti-inflammatory and anti-thrombogenic effects against COVID-19 using in silico and 3D-human vascular lung models, suggesting they could be repurposed as targeted therapies.

In silico and in vitro Demonstration of Homoharrintonine Antagonism of RBD-ACE2 Binding and its Anti-inflammatory and anti-thrombogenic Properties in a 3D human vascular lung model

This paper identifies Homoharringtonine as a potential repurposed drug for COVID-19 by demonstrating its ability to block RBD-ACE2 binding and show anti-inflammatory and anti-thrombogenic effects in a 3D human vascular lung model.